ANO1 and prostate carcinoma: Inhibiting calcium-activated chloride channels (CaCCs) can diminish the tumorigenic characteristics of ANO1, indicating that TMEM16A and its related channels are promising targets for the treatment of prostate cancer and other malignancies.